[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341004-105":59,"doc-detail-341004-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","use-of-micrornas-as-diagnostic-prognostic-and-therapeutic-tools-for-glioblastoma-review","Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma - review","","Glioblastoma (GB) is a highly aggressive central nervous system cancer whose molecular etiology remains incompletely understood, limiting curative options. Clinical diagnosis is often delayed until symptoms appear and typically relies on invasive exam, imaging, and biopsy. The review emphasizes less invasive blood-based biomarkers, focusing on microRNAs (miRNAs), which are stable in diverse body fluids. Dysregulated miRNAs are discussed as diagnostic and prognostic markers, molecular tools for subclassification, and therapeutic candidates, including current clinical challenges and future directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/use-of-micrornas-as-diagnostic-prognostic-and-therapeutic-tools-for-glioblastoma-review/341004/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/use-of-micrornas-as-diagnostic-prognostic-and-therapeutic-tools-for-glioblastoma-review/341004.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is there a need for less invasive diagnostic and prognostic tools in glioblastoma?","Question",{"text":112,"@type":113},"GB is usually diagnosed after symptoms appear and is confirmed through invasive physical examinations, imaging, and surgical biopsy. The review highlights the need for earlier and less invasive approaches that improve quality of life.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What makes microRNAs (miRNAs) suitable as blood-based biomarkers?",{"text":117,"@type":113},"miRNAs are small, non-coding RNAs shown to be very stable across many body fluids, including serum and cerebrospinal fluid. Circulating and exosome-contained miRNAs can support molecular classification of cancer subtypes.",{"name":119,"@type":110,"acceptedAnswer":120},"How might miRNAs contribute to treatment of glioblastoma?",{"text":121,"@type":113},"The review explains that miRNAs regulate multiple target genes and can function as tumor suppressors or oncogenes. Dysregulated miRNAs are linked to tumor progression and chemoresistance, and the therapeutic potential of miRNAs is discussed along with clinical challenges and future directions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341004,1790356456,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nUse of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma  \nDavid Valle-Garcia 1, Verónica Pérez de la Cruz 2, Itamar Flores 1, Aleli Salazar 1, Benjamín Pineda 1, * and Karla F. Meza-Sosa 2, *  \nCitation: Valle-Garcia, D.; Pérez de la Cruz, V.; Flores, I.; Salazar, A.; Pineda, B.; Meza-Sosa, K.F. Use of microRNAsas Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma. Int. J. Mol. Sci. 2024, 25, 2464. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25052464](doi.org/10.3390/ijms25052464)  \nAcademic Editor: Mohamed Raafat El-Gewely  \nReceived: 31 December 2023  \nRevised: 22 January 2024  \nAccepted: 29 January 2024  \nPublished: 20 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Laboratorio de Neuroinmunología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNNMVS), Mexico City 14269, Mexico; [david.valle.edu@gmail.com](david.valle.edu@gmail.com) (D.V.-G.); ifloresm1903@alumno.ipn.mx (I.F.); aleli.salazar@innn.edu.mx (A.S.)  \n2 Laboratorio de Neurobioquímica y Conducta, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNNMVS), Mexico City 14269, Mexico; [veped@yahoo.com.mx](veped@yahoo.com.mx)  \n* [Correspondence: benjamin.pineda@innn.edu.mx](Correspondence: benjamin.pineda@innn.edu.mx) (B.P.); [karla.meza@innn.edu.mx](karla.meza@innn.edu.mx) (K.F.M.-S.)  \nAbstract: Glioblastoma (GB) is the most aggressive and common type of cancer within the central nervous system (CNS). Despite the vast knowledge of its physiopathology and histology, its etiology at the molecular level has not been completely understood. Thus, attaining a cure has not been possible yet and it remains one of the deadliest types of cancer. Usually, GB is diagnosed when some symptoms have already been presented by the patient. This diagnosis is commonly based on a physical exam and imaging studies, such as computed tomography (CT) and magnetic resonance imaging (MRI), together with or followed by a surgical biopsy. As these diagnostic procedures are very invasive and often result only in the confirmation of GB presence, it is necessary to develop less invasive diagnostic and prognostic tools that lead to earlier treatment to increase GB patients’ quality of life. Therefore, blood-based biomarkers (BBBs) represent excellent candidates in this context. microRNAs (miRNAs) are small, non-coding RNAs that have been demonstrated to be very stable in almost all body fluids, including saliva, serum, plasma, urine, cerebrospinal fluid (CFS), semen, and breast milk. In addition, serum-circulating and exosome-contained miRNAs have been successfully used to better classify subtypes of cancer at the molecular level and make better choices regarding the best treatment for specific cases. Moreover, as miRNAs regulate multiple target genes and can also act as tumor suppressors and oncogenes, they are involved in the appearance, progression, and even chemoresistance of most tumors. Thus, in this review, we discuss how dysregulated miRNAs in GB can be used as early diagnosis and prognosis biomarkers as well as molecular markers to subclassify GB cases and provide more personalized treatments, which may have a better response against GB. In addition, we discuss the therapeutic potential of miRNAs, the current challenges to their clinical application, and future directions in the field.  \nKeywords: non-coding RNAs; microRNAs; miRNAs; glioma; glioblastoma; glioblastoma multiforme; GBM; glioma treatment; RNA therapy  \n1. Glioblastoma  \nGliomas are derived from glial cells. In addition to being the most lethal and representing 30% of all primary tumors in the adult ","cbCaipo3HgzWu6Sd","https://ap.wps.com/l/cbCaipo3HgzWu6Sd","pdf",1322778,28,"English","# Glioblastoma\n## Background and classification\n## Need for less invasive diagnostic and prognostic tools\n## MicroRNAs (miRNAs) as biomarkers and therapeutic targets","[{\"question\":\"Why is there a need for less invasive diagnostic and prognostic tools in glioblastoma?\",\"answer\":\"GB is usually diagnosed after symptoms appear and is confirmed through invasive physical examinations, imaging, and surgical biopsy. The review highlights the need for earlier and less invasive approaches that improve quality of life.\"},{\"question\":\"What makes microRNAs (miRNAs) suitable as blood-based biomarkers?\",\"answer\":\"miRNAs are small, non-coding RNAs shown to be very stable across many body fluids, including serum and cerebrospinal fluid. Circulating and exosome-contained miRNAs can support molecular classification of cancer subtypes.\"},{\"question\":\"How might miRNAs contribute to treatment of glioblastoma?\",\"answer\":\"The review explains that miRNAs regulate multiple target genes and can function as tumor suppressors or oncogenes. Dysregulated miRNAs are linked to tumor progression and chemoresistance, and the therapeutic potential of miRNAs is discussed along with clinical challenges and future directions.\"}]","Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma - review | PDF",1790039899,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84f29c0b5c28b1fcfbcdb6a2a2e9f9d9.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cc12b6e4c19a6e51c9799602a653009.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe22f36d9ded8af3e58560b41b6e01e4.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f486fcedc11e3906ed96e6a5cd3e38f8.webp",980,1385]